Austin-based AI-driven biotherapeutic research and technology firm ImmunoPrecise Antibodies (NASDAQ: IPA) makes key leadership changes. This includes appointment of Dr. Kamil Isaev to its board of directors and Jospeh Scheffler as interim CFO.
The company also announced the planned departure of Chris Buyse from its board.
A seasoned technology leader and venture strategist, Dr. Kamil brings three decades of expertise in AI, semiconductor technologies, and global R&D operations. He has held key leadership roles at Intel, Dell EMC, Align Technology, and ABRT VC. Dr. Kamil has played pivotal role in scaling R&D centers, driving AI-driven innovation, and leading high-impact cross-functional teams to bring emerging technologies to market.
Dr. Kamil currently serves as a Venture Partner at ABRT VC, where he leads the ABRT AI Lab and the VC Score project, developing AI-powered evaluation models to assess and rank AI startups, providing investors with data-driven insights to identify high-potential opportunities. His role at ABRT VC is focused on bridging cutting-edge AI research with commercialization strategies, helping AI-driven companies refine their go-to-market approach and maximize scalability.
Dr. Kamil previously held key leadership roles at Intel Corporation, where he served as Director of Developer Relations Engineering, overseeing global AI and software development teams. He led initiatives in AI computing optimization, GPU workload migration, and machine learning integration, working closely with partners to drive adoption of AI technologies. As Intel’s Country R&D General Manager, he spearheaded machine learning and deep learning deployment across the company’s ecosystem.
Beyond Intel, Dr. Kamil has led large-scale R&D and technology commercialization efforts. At Align Technology, he managed a 600+ engineer R&D division, driving digital transformation and Agile adoption. As Vice President of Operations at Caresyntax, he played a key role in the company’s U.S. expansion, integrating AI-driven insights into clinical workflows. At Dell EMC, he led solutions architecture for AI, healthcare, and video surveillance, focusing on bridging innovation with industry applications.
Dr. Kamil, a member of IEEE and a frequent AI industry speaker, holds an MSc and PhD in Physics from Moscow State University. “We are delighted to welcome Dr. Isaev,” said Dr. Jennifer Bath, IPA’s President and CEO. “His expertise in AI-driven innovation and commercialization aligns with our mission to advance biologics through cutting-edge technology.”
IPA’s new interim CFO, Joseph Scheffler as Interim CFO, is a seasoned finance professional with over 20 years of experience. He previously served as Interim Corporate Controller at Nidec-Kinetek, overseeing financial reporting for a $400 million global firm. “Joseph’s financial expertise will be instrumental in strengthening our strategy,” Dr. Bath stated.
Additionally, IPA confirmed the departure of Chris Buyse from the Board of Directors. “We appreciate Chris’s contributions during this strategic transition,” said Dr. Bath.
